dabigatran has been researched along with rifampin in 3 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (rifampin) | Trials (rifampin) | Recent Studies (post-2010) (rifampin) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 20,468 | 1,499 | 6,552 |
| Protein | Taxonomy | dabigatran (IC50) | rifampin (IC50) |
|---|---|---|---|
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.949 | |
| Caspase-1 | Homo sapiens (human) | 8.319 | |
| Alpha-synuclein | Homo sapiens (human) | 7.1 | |
| Enoyl-[acyl-carrier-protein] reductase [NADH] | Mycobacterium tuberculosis H37Rv | 0.03 | |
| DNA-directed RNA polymerase subunit beta | Mycobacterium tuberculosis H37Rv | 0.01 | |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Härtter, S; Koenen-Bergmann, M; Lemke, U; Nehmiz, G; Reilly, PA; Sharma, A; Timmer, W | 1 |
| Costales, C; Eatemadpour, S; Kimoto, E; Lazzaro, S; Varma, MV; Yamazaki, S | 1 |
| Bairlein, M; Denner, K; Fricke, R; Gieschen, H; Graudenz, K; Korjamo, T; Koskinen, M; Prien, O; von Bühler, CJ; Wilkinson, G; Zurth, C | 1 |
2 trial(s) available for dabigatran and rifampin
| Article | Year |
|---|---|
Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.
Topics: Administration, Oral; Adult; Area Under Curve; Benzimidazoles; Biological Availability; Dabigatran; Drug Interactions; Enzyme Inhibitors; Female; Glucuronides; Half-Life; Humans; Male; Prodrugs; Pyridines; Rifampin; Young Adult | 2012 |
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Topics: Aged; Cells, Cultured; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Enzyme Induction; Female; Humans; Itraconazole; Male; Membrane Transport Proteins; Microsomes, Liver; Midazolam; Middle Aged; Pyrazoles; Rifampin; Rosuvastatin Calcium | 2019 |
1 other study(ies) available for dabigatran and rifampin
| Article | Year |
|---|---|
Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction.
Topics: Administration, Oral; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dabigatran; Digoxin; Drug Interactions; Female; Gene Expression Regulation; Healthy Volunteers; Humans; Intestinal Mucosa; Male; Models, Biological; Propanolamines; Quinidine; Rifampin | 2019 |